{"id":"one-dose-test-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, which triggers an immune response and produces antibodies to fight the virus.","oneSentence":"This vaccine induces an immune response to prevent COVID-19 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:26.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease"}]},"trialDetails":[{"nctId":"NCT05334706","phase":"PHASE4","title":"A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)","status":"RECRUITING","sponsor":"Miquel Angel Pavon Ribas","startDate":"2022-09-13","conditions":"Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV","enrollment":69},{"nctId":"NCT07415252","phase":"PHASE3","title":"SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-06-05","conditions":"Varicella (Chickenpox)","enrollment":780},{"nctId":"NCT06435351","phase":"EARLY_PHASE1","title":"Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-06-12","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":16},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT03309033","phase":"","title":"Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-02","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm","enrollment":991},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT06680128","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2025-02-24","conditions":"Japanese Encephalitis Virus Disease","enrollment":402},{"nctId":"NCT07077616","phase":"EARLY_PHASE1","title":"Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2025-07-01","conditions":"Glioma","enrollment":29},{"nctId":"NCT05220397","phase":"PHASE3","title":"Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Mark Stegall","startDate":"2022-04-11","conditions":"Kidney Transplant Recipient","enrollment":468},{"nctId":"NCT06223919","phase":"PHASE3","title":"Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2023-12-16","conditions":"Monkeypox","enrollment":8686},{"nctId":"NCT05060939","phase":"NA","title":"SARS-CoV-2 Infection in COVID-19 Vaccinated Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2021-08-20","conditions":"COVID-19","enrollment":1072},{"nctId":"NCT06844487","phase":"PHASE3","title":"Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-05-29","conditions":"Mpox (Monkeypox), Vaccination, Immunogenicity","enrollment":344},{"nctId":"NCT06799494","phase":"PHASE4","title":"HPV Vaccine Reduced Dose","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-08-06","conditions":"HPV","enrollment":100},{"nctId":"NCT05972733","phase":"PHASE2","title":"Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults","status":"COMPLETED","sponsor":"HilleVax","startDate":"2023-08-01","conditions":"Gastroenteritis","enrollment":80},{"nctId":"NCT06243666","phase":"","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2024-02-20","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection","enrollment":2188},{"nctId":"NCT00911560","phase":"PHASE1, PHASE2","title":"Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-05-27","conditions":"Neuroblastoma","enrollment":374},{"nctId":"NCT05184114","phase":"NA","title":"Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-10-04","conditions":"COVID-19, Myocarditis","enrollment":162},{"nctId":"NCT01290055","phase":"PHASE4","title":"Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine","status":"COMPLETED","sponsor":"Sri Edupuganti","startDate":"2019-04-15","conditions":"Yellow Fever","enrollment":27},{"nctId":"NCT05765604","phase":"PHASE1","title":"Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2023-03-14","conditions":"COVID-19","enrollment":72},{"nctId":"NCT03981952","phase":"PHASE1","title":"Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-10-28","conditions":"Risk Reduction","enrollment":96},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT05027464","phase":"NA","title":"Developing and Testing a COVID-19 Vaccination Acceptance Intervention","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2022-04-05","conditions":"COVID-19 Vaccination","enrollment":338718},{"nctId":"NCT05898763","phase":"PHASE1, PHASE2","title":"TEIPP Immunotherapy in Patients With NSCLC","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2021-09-29","conditions":"Non Small Cell Lung Cancer","enrollment":26},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT04785352","phase":"NA","title":"Grandi Byen: Test of an Integrated Parenting and Nutrition Intervention","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-07-01","conditions":"Malnutrition, Child, Development, Child, Parenting","enrollment":600},{"nctId":"NCT05770180","phase":"PHASE2","title":"Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2023-03-30","conditions":"COVID-19","enrollment":450},{"nctId":"NCT03956056","phase":"PHASE1","title":"Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-02-13","conditions":"Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas","enrollment":12},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06259656","phase":"NA","title":"Correlation of Antibody Response to COVID-19 Vaccination in Pregnant Woman and Transplacental Passage Into Cord Blood.","status":"COMPLETED","sponsor":"Vachira Phuket Hospital","startDate":"2023-10-25","conditions":"Covid-19","enrollment":40},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":"COVID-19","enrollment":1750},{"nctId":"NCT03294135","phase":"PHASE4","title":"The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-05","conditions":"Virus Diseases","enrollment":194},{"nctId":"NCT06334510","phase":"","title":"Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-11-17","conditions":"GCP","enrollment":4900},{"nctId":"NCT05022407","phase":"","title":"COVID-19 and HIV in Health Workers in Mozambique","status":"COMPLETED","sponsor":"Instituto Nacional de Saúde, Mozambique","startDate":"2021-07-15","conditions":"Hiv, Covid19","enrollment":3231},{"nctId":"NCT04072159","phase":"NA","title":"Community Pharmacists Vaccinate Against Cancer","status":"COMPLETED","sponsor":"Arizona State University","startDate":"2019-04-01","conditions":"Human Papillomavirus Vaccines","enrollment":33},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT04935528","phase":"NA","title":"Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2021-06-02","conditions":"Cancer","enrollment":539},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT05525546","phase":"PHASE1","title":"Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2022-08-15","conditions":"Risk Reduction","enrollment":82},{"nctId":"NCT05932563","phase":"","title":"Study on the Epidemiological Characteristics of Female HPV Vaccination in China","status":"UNKNOWN","sponsor":"Fujian Maternity and Child Health Hospital","startDate":"2023-01-01","conditions":"Human Papillomavirus Vaccines, Adverse Effect, Epidemiology","enrollment":1700},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT05895110","phase":"NA","title":"To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-04-29","conditions":"COVID-19","enrollment":240},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05492643","phase":"NA","title":"The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2022-08-13","conditions":"SARS-CoV-2, Safety, Immunotoxicity","enrollment":1000},{"nctId":"NCT03594890","phase":"PHASE1","title":"Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects","status":"COMPLETED","sponsor":"Osivax","startDate":"2018-06-12","conditions":"Influenza","enrollment":72},{"nctId":"NCT04810117","phase":"","title":"Monitoring the IgG/IgM Antibodies in COVID-19 Patients","status":"COMPLETED","sponsor":"University of Sargodha","startDate":"2021-06-15","conditions":"COVID-19 Infections","enrollment":373},{"nctId":"NCT04553016","phase":"PHASE1","title":"A Study to Test Three Experimental HIV Vaccines in Healthy Adults.","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-08-16","conditions":"HIV-1-infection","enrollment":88},{"nctId":"NCT03954743","phase":"PHASE3","title":"Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-19","conditions":"Infections, Rotavirus","enrollment":1351},{"nctId":"NCT05095298","phase":"PHASE4","title":"Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-08-01","conditions":"COVID-19","enrollment":400},{"nctId":"NCT02861586","phase":"PHASE2","title":"Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2016-08-17","conditions":"Chikungunya Virus Infection","enrollment":263},{"nctId":"NCT03443427","phase":"PHASE2","title":"A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-20","conditions":"Respiratory Disorders","enrollment":200},{"nctId":"NCT04870021","phase":"PHASE4","title":"Hepatitis B Birth Dose for Newborns","status":"COMPLETED","sponsor":"Quaid-e-Azam University","startDate":"2015-03-15","conditions":"Hepatitis B, Immunization; Infection","enrollment":218},{"nctId":"NCT04779996","phase":"","title":"Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2021-02-16","conditions":"Covid19, Cancer, HIV Infections","enrollment":250},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT04648800","phase":"PHASE3","title":"Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland","status":"UNKNOWN","sponsor":"Hanna Czajka","startDate":"2020-07-07","conditions":"Covid19, BCG Vaccination Reaction, SARS-CoV Infection","enrollment":1000},{"nctId":"NCT02807623","phase":"NA","title":"Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation","status":"COMPLETED","sponsor":"Womack Army Medical Center","startDate":"2016-09","conditions":"Immune System and Related Disorders","enrollment":300},{"nctId":"NCT02993965","phase":"NA","title":"State Immunization Information Systems to Improve HPV Vaccination Rates","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-02-21","conditions":"Vaccine, Human Papiloma Virus Vaccine, HPV Vaccine","enrollment":77716},{"nctId":"NCT03057379","phase":"NA","title":"HPV IIS Reminder/Recall- New York State","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2017-02-27","conditions":"Reminder Systems","enrollment":30616},{"nctId":"NCT02645032","phase":"PHASE1","title":"Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2016-05-19","conditions":"Typhoid","enrollment":144},{"nctId":"NCT03933098","phase":"PHASE3","title":"Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2019-11-15","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT01511419","phase":"PHASE1","title":"Safety Trial of Live Attenuated Influenza (H7N3) Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-04","conditions":"Influenza, Avian Influenza","enrollment":40},{"nctId":"NCT00771615","phase":"PHASE2","title":"Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-16","conditions":"Influenza","enrollment":469},{"nctId":"NCT00814489","phase":"PHASE1","title":"Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-08","conditions":"Streptococcus Pneumoniae, Haemophilus Influenzae","enrollment":40},{"nctId":"NCT00764790","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Influenza","enrollment":3317},{"nctId":"NCT00923351","phase":"PHASE1, PHASE2","title":"Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06-02","conditions":"Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal","enrollment":44},{"nctId":"NCT00753272","phase":"PHASE3","title":"Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-15","conditions":"Influenza","enrollment":43695},{"nctId":"NCT00540592","phase":"PHASE2","title":"Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-08","conditions":"Influenza","enrollment":2007},{"nctId":"NCT03431246","phase":"PHASE3","title":"Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-10-01","conditions":"Human Papillomavirus Vaccines","enrollment":32},{"nctId":"NCT00819806","phase":"PHASE1","title":"CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors","status":"COMPLETED","sponsor":"Hassane M. Zarour, MD","startDate":"2009-01","conditions":"NY-ESO-1-expressing Tumors","enrollment":21},{"nctId":"NCT00707798","phase":"PHASE1","title":"Evaluation of Pneumococcal Vaccine Formulations in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-30","conditions":"Infections, Streptococcal","enrollment":157},{"nctId":"NCT02389322","phase":"PHASE2","title":"Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2015-03","conditions":"Tuberculosis","enrollment":1044},{"nctId":"NCT02806804","phase":"PHASE3","title":"Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60","status":"UNKNOWN","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2016-05","conditions":"Quadrivalent Influenza Virus Vaccine","enrollment":2400},{"nctId":"NCT01943305","phase":"PHASE2","title":"The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2013-10","conditions":"Yellow Fever, Encephalitis, Japanese","enrollment":84},{"nctId":"NCT00561002","phase":"PHASE4","title":"Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Influenza","enrollment":34},{"nctId":"NCT00778258","phase":"PHASE2","title":"Study of Milk Allergy and Tolerance in Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-08","conditions":"Food Hypersensitivity, Milk Hypersensitivity","enrollment":170},{"nctId":"NCT00886613","phase":"PHASE1","title":"A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Herpes Zoster","enrollment":120},{"nctId":"NCT01341704","phase":"PHASE2","title":"Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa","status":"COMPLETED","sponsor":"Vac4All","startDate":"2011-05","conditions":"Malaria","enrollment":800},{"nctId":"NCT01966224","phase":"PHASE1","title":"A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects","status":"COMPLETED","sponsor":"Immunomic Therapeutics, Inc.","startDate":"2013-09","conditions":"Allergic Rhinoconjunctivitis","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"one dose test vaccine","genericName":"one dose test vaccine","companyName":"Beijing Chaoyang District Centre for Disease Control and Prevention","companyId":"beijing-chaoyang-district-centre-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine induces an immune response to prevent COVID-19 infection. Used for Prevention of COVID-19 disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}